Join our daily newsletter At The Bell to receive exclusive market insights
- Biotech company Medlab Clinical (MDC) has been granted an Australian patent for its NanoCelle delivery platform
- Essentially, NanoCelle delivers drug formulations via an oral spray
- So far, product testing results have indicated the spray can lead to better absorption of the drugs, helping the formulation avoid ingested routes
- It can also potentially lower drug dosages and reduce the side effects of some formulations
- Medlab has also filed patent applications in other jurisdictions, such as the U.S., Europe and New Zealand
- On the market this afternoon, Medlab is up 3.03 per cent, trading for 17 cents per share
Biotech company Medlab Clinical (MDC) has been granted an Australian patent for its NanoCelle delivery platform.
Essentially, NanoCelle delivers drugs via an oral spray. The device sprays the formulation into the Oro-buccal membrane, which is located along the lining of the cheek and the roof of the mouth.
So far, product testing results have indicated the spray can lead to better absorption of the drugs, helping the formulation avoid ingested routes. It can also potentially lower drug dosages and reduce the side effects of some formulations
Medlab CEO, Sean Hall, is pleased with the patent and says NanoCelle is a key feature in Medlab’s leading drug, NanaBis.
“This is the first patent granted for our NanoCelle drug delivery platform, it is a huge validation of the science behind NanoCelle and its innovative mode of action,” he said.
“NanoCelle is used to greatly improve drug solubility issues resulting in improved absorption, metabolism and utilisation, giving us [Medlab] many options to improve prescription and over the counter medicines,” he added.
Medlab has also filed patent applications in the U.S., Europe, New Zealand, Canada, Hong Kong and Singapore.
On the market this afternoon, Medlab is up 3.03 per cent, trading for 17 cents per share at 2:06 pm AEST.
